Effect of Shilajatu Darvi Yoga on plasma expression of Apolipoprotein A-IV (ApoA-IV) and Thioredoxin interacting protein (TXNIP) in the patients of Madhumeha (Type 2 Diabetes Mellitus).

Differential expression of Apolipoprotein A-IV (ApoA-IV) and Thioredoxin interacting protein (TXNIP) in the plasma of Madhumeha (Type 2 Diabetes Mellitus) patients treated with Shilajatu Darvi Yoga: An Exploratory Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061750

Enrollment

110

Registered

2024-01-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Fasting plasma glucose: = 126 mg/dL – 200 mg/dL 2.2-h plasma glucose: >200 mg/dL – 350 mg/dL 3.Symptoms of diabetes plus random blood glucose = 200 mg/dl. 4.HbA1C: 6.5% - 10% 5.Patients in between 40 and 60 years of either sex.

Exclusion criteria

Exclusion criteria: 1.Patients of type-1 diabetes mellitus. 2.Cases with severe diabetic complications such as cardiac disease, nephropathy, and foot ulcer. 3.Patients with chronic diseases such as Tuberculosis, Bronchial asthma, Chronic renal failure, HIV, and Hepatitis. 4.Patient below 40 years and above 60 years. 5.Patients taking medication that may cause rapid glucose rise e.g. steroids, antipsychotics. 6.Patients with acute pancreatic damage, including pancreatic surgery. 7.Pregnancy.

Design outcomes

Primary

Measure	Time frame
Modulatory effect of Shilajatu Darvi Yoga on the plasma levels of protein apoA-IV & TXNIP in type 2 diabetic patients will be evaluated.Timepoint: Baseline. 60th and 90th day	—

Secondary

Measure	Time frame
Effect of Shilajatu Darvi Yoga on Blood sugar level (Fasting & PP), HbA1c, CBC, LFT, KFT, & Lipid profile in patients of Type 2 Diabetes Mellitus will be determined.Timepoint: Fasting & PP blood sugar levels at Baseline, 30th, 60th & 90th day. HbA1c, CBC, LFT, KFT & Lipid profile at Baseline & 90th day.	—

Countries

India

Contacts

Public ContactDr Rohit Singh

All India Institute of Ayurveda

drpramod88@gmail.com8930625596

Outcome results